[의학신문·일간보사=김상일 기자]In February 2018, Gilead Sciences Korea Truvada was approved for an expanded indication as a pre-exposure prophylaxis (PrEP) treatment before exposure to HIV-1.
With this, Gilead Science Korea has a 360-degree portfolio of HIV from treatment to prevention. It has been 9 years since Truvada was first approved for the treatment of HIV in May 2010.
Since then, Truvada will receive insurance benefits for ‘partners of HIV-infected people’ in June 2019, and it is evaluated that the ‘HIV prevention era’ has begun.
In Korea, there are very few types of disease prevention as a treatment rather than a vaccination, so Truvada’s insurance coverage for HIV prevention is a remarkable achievement.
If the nature of HIV disease has been accompanied by social prejudice and stigma, high-risk groups at high risk of infection can voluntarily and preemptively prevent HIV infection by taking one tablet of Truvada a day on their own.
Now, the high-risk group has become a ‘self-directed preventable disease’. It is also possible to reduce the medical and social and economic costs resulting from the reduction of the risk of infection in society through prevention of high-risk groups of HIV infection.
This is because the clinical rationale behind Truvada’s approval and reimbursement for HIV prevention purposes, which opened the era of HIV prevention, was clear. Truvada has demonstrated a significant prophylactic effect and safety profile in a large clinical study in a large number of populations at high risk of HIV infection.
Foreign countries such as the US Centers for Disease Control and Prevention, the UK government, and the Taiwan Centers for Disease Control and Prevention strongly recommend PrEP therapy, such as providing free PrEP therapy or implementing various programs.
As such, overseas countries implemented active HIV prevention measures, including PrEP therapy, to effectively and effectively control new HIV infection.
However, it is pointed out that PrEP therapy has a positive effect on reducing the number of actual new infections, and although it has been confirmed that it is cost-effective through a number of cost-effectiveness analyzes at home and abroad, it is pointed out that the target for domestic reimbursement is limited.
Partners of HIV-infected persons are of the high-risk group, where the risk of infection is not substantially high.